glp 1 gip glucagon triple agonist Schematic illustration of monoagonists, dual agonists and retatrutide triple agonist glp-1 gip

EXAMPLES OF SWITCHING TO OW SEMAGLUTIDE Four case studies are provided in Figure 3, based on the authors clinical experience, to illustrate the considerations when switching from one GLP1RA to another, using OW semaglutide as an example

Because many people eat significantly lesssuch as 35% fewer total calories 4 while taking these medications, according to recent researchit becomes especially important to prioritize a nutrient-dense diet in order to limit deficiencies and the side effects they can cause

doi: 10.1210/jc.2014-3415 [DOI] [PubMed] [Google Scholar] 8.Li H, Yu G, Huang Q, et al

The effects of GLP-1RAs on multiple human organizations, source: reference [2] Data from Novo Nordisk's Phase III clinical trial showed that liraglutide 3.0 mg resulted in a 5% weight loss in approximately 62% of obese patients and a 10% weight loss in 34% of patients after a 56-week treatment period

Pharmacol Rev 2016;68:9541013.ArticlePubMedPMC 30

Safety profile: mostly mild to moderate gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) that are transient in nature